Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status

Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability. Unlike molecular targeting agents, such as gefitinib, lung cancer patients with a p...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kyoichi Kaira, Hisao Imai, Atsuto Mouri, Ou Yamaguchi, Hiroshi Kagamu
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	<sup>18</sup>F-FDG PET PD-1 blockade immunotherapy lung cancer long-term survival metabolic response Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/79dcc5017da044948fc6bc848e668f56
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:79dcc5017da044948fc6bc848e668f56
record_format	dspace
spelling	oai:doaj.org-article:79dcc5017da044948fc6bc848e668f562021-11-25T18:19:08ZClinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status10.3390/medicina571112731648-91441010-660Xhttps://doaj.org/article/79dcc5017da044948fc6bc848e668f562021-11-01T00:00:00Zhttps://www.mdpi.com/1648-9144/57/11/1273https://doaj.org/toc/1010-660Xhttps://doaj.org/toc/1648-9144Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability. Unlike molecular targeting agents, such as gefitinib, lung cancer patients with a poor performance status (PS) display unsatisfactory clinical improvements after ICI treatment. Several previous reports also demonstrated that the PS is identified as one of the most probable prognostic factors for predicting poor outcomes after ICI treatment. However, first-line pembrolizumab seemed to be effective for lung cancer patients with a PS of 2 if PD-L1 expression was greater than 50%. Currently, the induction of ICIs in patients with lung cancer with a poor PS is controversial. These problems are discussed in this review.Kyoichi KairaHisao ImaiAtsuto MouriOu YamaguchiHiroshi KagamuMDPI AGarticle<sup>18</sup>F-FDG PETPD-1 blockadeimmunotherapylung cancerlong-term survivalmetabolic responseMedicine (General)R5-920ENMedicina, Vol 57, Iss 1273, p 1273 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	<sup>18</sup>F-FDG PET PD-1 blockade immunotherapy lung cancer long-term survival metabolic response Medicine (General) R5-920
spellingShingle	<sup>18</sup>F-FDG PET PD-1 blockade immunotherapy lung cancer long-term survival metabolic response Medicine (General) R5-920 Kyoichi Kaira Hisao Imai Atsuto Mouri Ou Yamaguchi Hiroshi Kagamu Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
description	Immune checkpoint inhibitors (ICIs) are standard treatments for patients with lung cancer. PD-1/PD-L1 or CTLA4 antibodies are chosen as the first-line therapy, contributing to the long-term survival and tolerability. Unlike molecular targeting agents, such as gefitinib, lung cancer patients with a poor performance status (PS) display unsatisfactory clinical improvements after ICI treatment. Several previous reports also demonstrated that the PS is identified as one of the most probable prognostic factors for predicting poor outcomes after ICI treatment. However, first-line pembrolizumab seemed to be effective for lung cancer patients with a PS of 2 if PD-L1 expression was greater than 50%. Currently, the induction of ICIs in patients with lung cancer with a poor PS is controversial. These problems are discussed in this review.
format	article
author	Kyoichi Kaira Hisao Imai Atsuto Mouri Ou Yamaguchi Hiroshi Kagamu
author_facet	Kyoichi Kaira Hisao Imai Atsuto Mouri Ou Yamaguchi Hiroshi Kagamu
author_sort	Kyoichi Kaira
title	Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
title_short	Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
title_full	Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
title_fullStr	Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
title_full_unstemmed	Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status
title_sort	clinical effectiveness of immune checkpoint inhibitors in non-small-cell lung cancer with a poor performance status
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/79dcc5017da044948fc6bc848e668f56
work_keys_str_mv	AT kyoichikaira clinicaleffectivenessofimmunecheckpointinhibitorsinnonsmallcelllungcancerwithapoorperformancestatus AT hisaoimai clinicaleffectivenessofimmunecheckpointinhibitorsinnonsmallcelllungcancerwithapoorperformancestatus AT atsutomouri clinicaleffectivenessofimmunecheckpointinhibitorsinnonsmallcelllungcancerwithapoorperformancestatus AT ouyamaguchi clinicaleffectivenessofimmunecheckpointinhibitorsinnonsmallcelllungcancerwithapoorperformancestatus AT hiroshikagamu clinicaleffectivenessofimmunecheckpointinhibitorsinnonsmallcelllungcancerwithapoorperformancestatus
_version_	1718411328637370368

Clinical Effectiveness of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with a Poor Performance Status

Ejemplares similares